Male breast cancer according to tumor subtype and race: A population-based study

Cancer

Volumn 119, Issue 9, 2013, Pages 1611-1617

  Chavez Macgregor, Mariana ^a   Clarke, Christina A ^b   Lichtensztajn, Daphne ^b   Hortobagyi, Gabriel N ^a   Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

Author keywords

breast cancer; breast cancer subtypes; males; population based study; race

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE BREAST; NEGRO; PRIORITY JOURNAL; RACE; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

AGED; BREAST NEOPLASMS, MALE; CALIFORNIA; CONTINENTAL POPULATION GROUPS; GENES, ERBB-2; HUMANS; MALE; POPULATION SURVEILLANCE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84876673270     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27905     Document Type: Article

References (25)

1. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN,. Breast carcinoma in men: a population-based study. Cancer. 2004; 101: 51-57.
2. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
3. Giordano SH, Buzdar AU, Hortobagyi GN,. Breast cancer in men. Ann Intern Med. 2002; 137: 678-687.
4. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010; 28: 2114-2122.
5. Anderson WF, Althuis MD, Brinton LA, Devesa SS,. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004; 83: 77-86.
6. Stalsberg H, Thomas DB, Rosenblatt KA, et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control. 1993; 4: 143-151.
7. Leach IH, Ellis IO, Elston CW,. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol. 1992; 45: 942.
8. Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer. 1998; 83: 1947-1955.
9. Gattuso P, Reddy VB, Green LK, Castelli MJ, Wick RM,. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol. 1995; 2: 199-206.
10. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D,. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001; 182: 389-392.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
12. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R,. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of 4 randomized trials. J Clin Oncol. 2001; 19: 343-353.
13. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; 127: 471-478.
14. Bauer KR, Brown M, Creech C, Schlang NC, Caggiano V,. Data quality assessment of HER2 in the Sacramento region of the California Cancer Registry. J Regist Manage. 2007; 34: 4-7.
15. Parise CA, Bauer KR, Brown MM, Caggiano V,. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009; 15: 593-602.
16. Muir D, Kanthan R, Kanthan SC,. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003; 127: 36-41.
17. Curigliano G, Colleoni M, Renne G, et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol. 2002; 13: 895-902.
18. Arslan UY, Oksuzoglu B, Ozdemir N, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012; 29: 554-560.
19. Chavez-Macgregor M, Litton J, Chen H, et al. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010; 116: 4168-4177.
20. Sparano J, Wang W, Stears V, et al. Black race is associated with a worse outcome in patients with hormone receptor positive, Her2-normal breast cancer treated with chemohormonal therapy [abstract]. Cancer Res. 2010; 69 (suppl 3). Abstract 494s.
21. O'Malley C, Shema S, White E, Glaser S,. Incidence of male breast cancer in California, 1988-2000: racial/ethnic variation in 1759 men. Breast Cancer Res Treat. 2005; 93: 145-150.
22. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97: 1254-1261.
23. Neven P, Pochet N, Drijkoningen M, et al. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. J Clin Oncol 24: 2595, 2006; author reply 2595-2597.
24. Thakkar JP, Mehta DG,. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist. 2011; 16: 276-285.
25. Yu KD, Liu GY, Di GH, et al. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast. 2007; 16: 307-315.